Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data
In general, transitions between GLP-1 agonists follow a washout-and-titrate approach
While it may contribute to weight loss, its use for weight management is considered off-label, which can complicate insurance approvals unless the patient has a confirmed diabetes diagnosis and meets stringent criteria like elevated A1C levels and prior medication failures
A person carrying the FTO rs9939609 risk variant may store fat preferentially in the abdomen and experience slower overall weight loss, while someone without this variant might see more rapid scale changes
.webp)
